Teva Pharma Ind Shs Sponsored American Deposit Receipt Repr 1 Sh $54.46

up +0.46


11/7/2014 04:01 PM  |  NYSE : TEVA  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get TEVA Trend Analysis - it has outperformed the S&P 500 by 22%

Partner Headlines

  1. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  2. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  3. Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest ...

    Benzinga
  4. Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd

    GuruFocus
  5. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  6. Teva Pharmaceutical

    IBD
  7. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  8. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  9. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  10. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  11. Teva to buy Labrys Biologics

    IBD
  12. Chicago sues painkiller firms

    IBD
  13. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  14. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  15. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  16. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  17. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  18. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  19. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries Ltd.

    Benzinga
  20. Teva EPS tops; rivals seen?

    IBD
  21. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  22. Earnings Scheduled For May 1, 2014

    Benzinga
  23. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  24. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  25. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  26. Morning Market Losers

    Benzinga
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY ...

    Benzinga
  29. Nasdaq Could Be in for a Bounce

    FoxBusiness
  30. Actavis got a Pfizer

    IBD
  31. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received Tenative ...

    Benzinga
  32. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  33. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  34. Teva Announces First Approval and Launch of Generic Lovaza® Capsules in ...

    Benzinga
  35. Market Wrap For April 7: Bears In Complete Control As Markets Get Hammered ...

    Benzinga
  36. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  37. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy

    Benzinga
  38. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  39. Market Wrap For March 28: Markets Still Positive Despite Giving Up Early ...

    Benzinga
  40. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  41. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  42. Forest Laboratories' Recovery

    GuruFocus
  43. Should You Buy Actavis?

    GuruFocus
  44. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  45. UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

    Benzinga
  46. UPDATE: Morgan Stanley Upgrades Teva Pharmaceutical Industries on Copaxone ...

    Benzinga
  47. Benzinga's Top Upgrades

    Benzinga
  48. US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

    Benzinga
  49. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  50. Pfizer Loses Bid to Hold Celebrex Exclusivity to '15

    FoxBusiness
Trading Center